Join Professor Tom Solomon as he hosts a regular discussion on Coronavirus and its impact on science and society in Liverpool. Tom talks with leading Liverpool researchers about the scientific progress being made in the city to tackle the virus and chats about the wider impact of the pandemic with some famous local faces.
His guests this time are broadcaster and BBC Radio 4 presenter Jane Garvey and Professor Saye Khoo, Professor in the Department of Pharmacology at the University of Liverpool, and Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital.
Professor Tom Solomon is Director of the UK's Emerging Infections Research Unit based as the University of Liverpool, is on the NHS front line at the Walton NeuroCentre and Royal Liverpool University Hospital, and appears regularly on television and radio discussing science.
Liverpool born Broadcaster, Jane Garvey is currently a presenter of BBC Radio 4's Woman's Hour, and co-founder of the weekly podcast series Fortunately.
Jane studied English at The University of Birmingham before joining BBC Hereford and Worcester to present their Breakfast Show.
Garvey's was the first voice on BBC Radio 5 Live when it launched in 1994. While she was with Radio 5 Live she presented the breakfast programme and the relaunched Midday show, and co-presented its Drive show on weekday afternoons with Peter Allen, for which she and Allen won four Sony Gold Awards.
Jane will leave Woman's Hour later this year and will host her own new Radio 4 series in the new year.
Professor Saye Khoo, MD, PhD, is Professor in the Department of Pharmacology at the University of Liverpool, and Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital. His research focuses on infection pharmacology, including optimising dosing for special populations and drug-drug interactions in the treatment and prevention of HIV and TB. He leads the international DolPHIN consortium studying safe and effective use of anti-retrovirals in pregnancy, and provides clinical leadership for Liverpool Drug Interactions programme (www.drug-interactions.org). He is also Chief Investigator for the AGILE Phase I/II platform for SARS CoV2 therapies (www.agiletrial.net).